LTR Pharma Signs Binding Term Sheet for US ROXUS Launch via Shed Telehealth
LTR Pharma has executed a binding term sheet with Shed Holdings LLC to establish its first commercial route-to-market for ROXUS® in the United States, targeting 150,000 prescription units during the first 12 months from Commercial Launch. The arrangement grants Shed two-year direct-to-consumer telehealth exclusivity, subject to ongoing performance requirements, positioning LTR Pharma to enter the world’s largest erectile dysfunction market.
LTR Pharma secures first U.S. commercial framework for ROXUS with 150,000-unit volume target
The binding term sheet represents LTR Pharma’s first commercial volume framework established in support of its planned U.S. commercialisation strategy for ROXUS®. Under the arrangement, LTR Pharma retains ownership of the product and intellectual property whilst Shed provides patient acquisition, telehealth infrastructure, and commercial capabilities required to support patient access.
The performance-based structure includes a minimum commercial volume target of 150,000 ROXUS prescription units during the first 12 months from Commercial Launch, subject to supply and execution of Definitive Agreements. This volume commitment is binding under the term sheet, providing LTR Pharma with quantifiable commercial expectations from the outset.
Shed’s consumer-facing men’s health platform, Mavrox, will serve as the primary commercialisation and distribution channel for ROXUS in the United States. ROXUS will be supplied through the U.S. Section 503A personalised medicine pathway via LTR Pharma’s designated U.S. 503A pharmacy partner. The rapid-acting intranasal format differentiates ROXUS from traditional oral PDE5 inhibitors and aligns with the on-demand, digitally enabled treatment access increasingly preferred by patients in this category.
LTR Pharma’s intranasal delivery platform has demonstrated a 10-minute median onset in Phase II interim data, compared with 60 minutes for oral vardenafil, providing clinical context for why the rapid-acting format is positioned as a differentiated alternative to traditional PDE5 inhibitors in the U.S. men’s health market.
| Term | Detail | Binding Status |
|---|---|---|
| Minimum Commercial Volume | 150,000 ROXUS prescription units in first 12 months from Commercial Launch | Binding |
| Exclusivity Period | Two years from Commercial Launch in U.S. DTC telehealth channel | Binding |
| Initial Term | Two years from Commercial Launch with annual auto-renewal | Subject to Definitive Agreements |
| Definitive Agreements Timeline | 60 days from effective date | Binding timeline requirement |
When big ASX news breaks, our subscribers know first
How the U.S. telehealth distribution model works
The commercial structure positions LTR Pharma as the product owner, intellectual property holder, and supplier, whilst Shed provides the patient acquisition, telehealth, and commercial infrastructure supporting patient access to ROXUS in the United States. This division of responsibilities allows LTR Pharma to maintain control of the product whilst leveraging Shed’s established digital healthcare delivery capabilities.
Shed will be responsible for patient acquisition, platform operations, clinical infrastructure, and related marketing costs. Mavrox, Shed’s consumer-facing men’s health platform, will function as the primary commercialisation and distribution channel for ROXUS.
ROXUS will be supplied through the U.S. Section 503A personalised medicine pathway via LTR Pharma’s designated U.S. 503A pharmacy partner. This pathway enables LTR Pharma to enter the U.S. market whilst longer-term regulatory strategies may progress in parallel. The two-year exclusivity period runs from Commercial Launch and remains subject to ongoing performance requirements, including adherence to the minimum commercial volume provisions.
The parties must execute Definitive Agreements within 60 days of the effective date. If Definitive Agreements are not executed within this period, the term sheet terminates, except for surviving binding provisions, and exclusivity ends automatically.
What is the U.S. Section 503A personalised medicine pathway?
ROXUS will be supplied through the U.S. Section 503A personalised medicine pathway via LTR Pharma’s designated U.S. 503A pharmacy partner.
This approach suits ROXUS’s rapid-acting intranasal format and the direct-to-consumer telehealth model through which Shed will distribute the product. Patients access the treatment through Mavrox’s digital platform, with prescriptions fulfilled by LTR Pharma’s designated U.S. pharmacy partner under Section 503A provisions. The pathway provides LTR Pharma with a commercial entry point into the U.S. market whilst longer-term regulatory strategies may be pursued in parallel.
Binding commitments and performance safeguards
The agreement constitutes a binding term sheet rather than a completed, unconditional distribution agreement. The binding elements include the minimum commercial volume provisions and exclusivity provisions. The broader commercial terms remain subject to negotiation and documentation in Definitive Agreements within 60 days of the effective date.
If Shed does not meet the minimum volume requirements, LTR Pharma has the right to convert the arrangement from exclusive to non-exclusive. This performance safeguard protects LTR Pharma from underperformance whilst providing Shed with an exclusivity incentive to deliver the committed volume. The two-year initial term runs from Commercial Launch, with annual auto-renewal unless either party elects not to renew.
Commercial Launch remains subject to three specific conditions:
- Execution of Definitive Agreements
- Onboarding of LTR Pharma’s designated U.S. pharmacy fulfilment partner
- Completion of technology transfer activities and satisfaction of customary launch-readiness conditions
The minimum commercial volume commitment and exclusivity provisions are binding under the term sheet. The broader commercial arrangements, including pricing, supply terms, and operational protocols, remain subject to the execution of Definitive Agreements and the satisfaction of customary launch-readiness conditions.
Management commentary
Lee Rodne, Executive Chairman, LTR Pharma
“This is a defining step in our US commercialisation strategy. The binding term sheet with Shed establishes our first direct route to market in the world’s largest erectile dysfunction market and provides a scalable patient acquisition and telehealth channel for ROXUS. Importantly, the arrangement combines an established U.S. telehealth platform with a performance-based commercial framework and minimum volume targets, creating a clear pathway toward commercial launch and revenue generation. We believe this framework positions ROXUS to become a leading intranasal treatment option within the rapidly growing U.S. men’s health market.”
Morley Baker, CEO, Shed
“We believe ROXUS represents a highly differentiated addition to the men’s health category. Its rapid-acting intranasal delivery platform offers patients an alternative to traditional oral therapies and aligns well with consumer needs. As we continue expanding our men’s health offering, we see significant opportunity for ROXUS to address an important unmet need and become a valuable treatment option for patients seeking greater flexibility and spontaneity in their care. We’re thrilled to work with LTR Pharma to bring access to ROXUS to consumers across the United States.”
The next major ASX story will hit our subscribers first
Next steps and pathway to U.S. revenue
The parties will now progress Definitive Agreements over the next 60 days, alongside launch readiness activities and integration with LTR Pharma’s designated U.S. pharmacy fulfilment partner. If Definitive Agreements are not executed within the 60-day timeline, the term sheet terminates (except for surviving binding provisions) and exclusivity ends automatically.
Once Commercial Launch conditions are satisfied, the 150,000-unit minimum volume target provides a quantifiable revenue benchmark for Year 1 post-Commercial Launch. The performance-based structure protects LTR Pharma through the non-exclusivity conversion right if volume requirements are not met, whilst the two-year exclusivity period provides Shed with commercial incentive to deliver the committed prescription volumes.
ROXUS is positioned to address the U.S. men’s health market through Shed’s established telehealth platform, which has demonstrated capability in patient acquisition, recurring prescription programmes, and digital healthcare delivery across multiple therapeutic categories. The binding term sheet establishes LTR Pharma’s first commercial route-to-market framework in the United States, with the 60-day Definitive Agreements timeline providing investors with a near-term catalyst to monitor.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX biotech news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements break across the healthcare and biotech sectors.